Risk of Anaphylaxis with Repeated Courses of Rasburicase: A Research on Adverse Drug Events and Reports (RADAR) Project-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Risk of Anaphylaxis with Repeated Courses of Rasburicase: A Research on Adverse Drug Events and Reports (RADAR) Project

Published:2015-01-08 Issue:2 Volume:38 Page:183-187
ISSN:0114-5916
Container-title:Drug Safety
language:en
Short-container-title:Drug Saf

Author:

Allen Katherine C.,Champlain Amanda H.,Cotliar Jonathan A.,Belknap Steven M.,West Dennis P.,Mehta Jayesh,Trifilio Steven M.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Toxicology

Link

http://link.springer.com/content/pdf/10.1007/s40264-014-0255-7.pdf

Reference16 articles.

1. Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011;364(19):1844–54.

2. Rasburicase [package insert]. Bridgewater: Sanofi-Aventis US LLC; 2009.

3. Abu-Alfa AK, Younes A. Tumor lysis syndrome and acute kidney injury: evaluation, prevention, and management. Am J Kidney Dis. 2010;55(5 Suppl 3):S1–13.

4. Chester KA, Baker M, Mayer A. Overcoming the immunologic response to foreign enzymes in cancer therapy. Expert Rev Clin Immunol. 2005;1(4):549–59.

5. Schellekens H. Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant. 2005;20(Suppl 6):63–9.

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hyperuricemia and its related diseases: mechanisms and advances in therapy;Signal Transduction and Targeted Therapy;2024-08-28

2. A case report of anaphylaxis caused by initial administration of rasburicase resulting in death just before the treatment of diffuse large B cell lymphoma;2024-04-11

3. Engineered Flt3L Drives Tolerogenic State to Attenuate Anti-drug Antibody Responses;2024-03-27

4. Acute tumor lysis syndrome — an urgent multidisciplinary problem in pediatric hematology;Russian journal of hematology and transfusiology;2024-03-19

5. PEGylated porcine–human recombinant uricase: A novel fusion protein with improved efficacy and safety for the treatment of hyperuricemia and renal complications;Open Life Sciences;2024-01-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3